Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Initial public offering nets $80.2mm for TCR2 Therapeutics

Executive Summary

Immuno-oncology firm TCR2 Therapeutics Inc. netted $80.2mm through its initial public offering of 5.75mm common shares (including the overallotment) at $15, the mid-point of the company’s $14-16 intended range.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies